Outlook Therapeutics, Inc.
Financial highlights
| Metric | FY September 30, 2025 | FY September 30, 2024 | FY September 30, 2023 | FY September 30, 2022 | FY September 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — |
| Gross profit | $57,205 | — | — | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M |
| Operating expenses | — | — | — | — | $51.7M |
| Cost of revenue | $1.4M | — | — | — | — |
| Cash from operations | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M |
| Total debt | — | — | $35.6M | $11.1M | $11.8M |
Shares outstanding 120.9M · Free float 76.8%
Annual filing data through FY ended September 30, 2025; float as of June 27, 2026.